Aim Real-world predictors of major bleeding (MB) have been well-studied among warfarin
users, but not among all direct oral anticoagulant (DOAC) users diagnosed with atrial …

Background No scores presently exist to predict bleeding in atrial fibrillation (AF)
populations using direct oral anticoagulants (DOACs). We used data from two independent …

Background In patients with atrial fibrillation (AF) treated with direct oral anticoagulants
(DOAC), bleeding risk scores provide only modest discrimination for major or intracranial …

Background High risk of intracranial hemorrhage (ICH) is a leading reason for withholding
anticoagulation in patients with atrial fibrillation (AF). We aimed to develop a claims-based …

Objective Balancing bleeding risk and stroke risk in patients with atrial fibrillation (AF) is a
common challenge. Though several bleeding risk scores exist, most have not included …

BACKGROUND: Current clinical decision tools for assessing bleeding risk in individuals
with atrial fibrillation (AF) have limited performance and were developed for individuals …

Objective Despite extensive use of oral anticoagulation (OAC) in patients with atrial
fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy …

Introduction Direct-acting oral anticoagulants (DOACs) are associated with risk of major
bleeding. This study evaluated the incremental healthcare economic burden of patients with …

Background Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and
GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example …

What is known and objective Bleeding risk scores (BRS s) aid in the assessment of oral
anticoagulant‐related bleeding risk in patients with atrial fibrillation. Ideally, the applicability …